Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;43(7):1091-1100.
doi: 10.1038/s41587-024-02391-0. Epub 2024 Oct 7.

Multiplexed, image-based pooled screens in primary cells and tissues with PerturbView

Affiliations

Multiplexed, image-based pooled screens in primary cells and tissues with PerturbView

Takamasa Kudo et al. Nat Biotechnol. 2025 Jul.

Erratum in

  • Author Correction: Multiplexed, image-based pooled screens in primary cells and tissues with PerturbView.
    Kudo T, Meireles AM, Moncada R, Chen Y, Wu P, Gould J, Hu X, Kornfeld O, Jesudason R, Foo C, Höckendorf B, Corrada Bravo H, Town JP, Wei R, Rios A, Chandrasekar V, Heinlein M, Chuong AS, Cai S, Lu CS, Coelho P, Mis M, Celen C, Kljavin N, Jiang J, Richmond D, Thakore P, Benito-Gutiérrez E, Geiger-Schuller K, Hleap JS, Kayagaki N, de Sousa E Melo F, McGinnis L, Li B, Singh A, Garraway L, Rozenblatt-Rosen O, Regev A, Lubeck E. Kudo T, et al. Nat Biotechnol. 2025 Jul;43(7):1202. doi: 10.1038/s41587-025-02602-2. Nat Biotechnol. 2025. PMID: 40011638 No abstract available.

Abstract

Optical pooled screening (OPS) is a scalable method for linking image-based phenotypes with cellular perturbations. However, it has thus far been restricted to relatively low-plex phenotypic readouts in cancer cell lines in culture due to limitations associated with in situ sequencing of perturbation barcodes. Here, we develop PerturbView, an OPS technology that leverages in vitro transcription to amplify barcodes before in situ sequencing, enabling screens with highly multiplexed phenotypic readouts across diverse systems, including primary cells and tissues. We demonstrate PerturbView in induced pluripotent stem cell-derived neurons, primary immune cells and tumor tissue sections from animal models. In a screen of immune signaling pathways in primary bone marrow-derived macrophages, PerturbView uncovered both known and novel regulators of NF-κB signaling. Furthermore, we combine PerturbView with spatial transcriptomics in tissue sections from a mouse xenograft model, paving the way to in situ screens with rich optical and transcriptomic phenotypes. PerturbView broadens the scope of OPS to a wide range of models and applications.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Genentech has submitted a provisional patent application that is based on the technology described in this manuscript. All authors are or were employed by Genentech, Inc., South San Francisco, California, at the time of their contribution to this work. A.R. is a cofounder and equity holder of Celsius Therapeutics and an equity holder in Immunitas and, until 31 July 2020, was a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. T.K. is a shareholder of Genomelink, Inc. E.L. is an equity holder in insitro, Inc. A.M.M., R.M., Y.C., P.W., J.G., X.H., O.K., R.J., C.F., B.H., H.C.B., J.P.T., R.W., A.S.C., M.M., C.C., N. Kljavin, J.J., D.R., P.T., E.B.-G., K.G.-S., J.S.H., N. Kayagaki, F.d.S.M., L.M., B.L., A.S., L.G., O.R.-R., A.R. and E.L. are equity holders in Roche.

References

    1. Shalem, O. et al. Genome-scale CRISPR–Cas9 knockout screening in human cells. Science 343, 84–87 (2014). - PubMed
    1. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR–Cas9 system. Science 343, 80–84 (2014). - PubMed
    1. Dixit, A. et al. Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell 167, 1853–1866 (2016). - PubMed - PMC
    1. Jaitin, D. A. et al. Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNA-seq. Cell 167, 1883–1896 (2016). - PubMed
    1. Adamson, B. et al. A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell 167, 1867–1882 (2016). - PubMed - PMC

LinkOut - more resources